Last reviewed · How we verify
Aldoxorubicin HCl
Aldoxorubicin HCl is a antitumor antibiotic Small molecule drug developed by ImmunityBio, Inc.. It is currently in Phase 2 development for Solid tumors.
Aldoxorubicin HCl is a prodrug that selectively releases doxorubicin in acidic environments, such as tumor cells, to exert its cytotoxic effects.
Aldoxorubicin HCl is a prodrug that selectively releases doxorubicin in acidic environments, such as tumor cells, to exert its cytotoxic effects. Used for Solid tumors.
At a glance
| Generic name | Aldoxorubicin HCl |
|---|---|
| Sponsor | ImmunityBio, Inc. |
| Drug class | antitumor antibiotic |
| Target | DNA topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
The selective release of doxorubicin from Aldoxorubicin HCl occurs in the acidic lysosomes of cancer cells, leading to DNA damage and apoptosis. This mechanism aims to reduce systemic toxicity associated with conventional doxorubicin administration.
Approved indications
- Solid tumors
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (PHASE2)
- QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. (PHASE1, PHASE2)
- QUILT-3.088: NANT Pancreatic Cancer Vaccine (PHASE2)
- QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (PHASE2)
- QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine (PHASE1, PHASE2)
- QUILT-3.080: NANT Pancreatic Cancer Vaccine (PHASE1, PHASE2)
- QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (PHASE1, PHASE2)
- QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aldoxorubicin HCl CI brief — competitive landscape report
- Aldoxorubicin HCl updates RSS · CI watch RSS
- ImmunityBio, Inc. portfolio CI
Frequently asked questions about Aldoxorubicin HCl
What is Aldoxorubicin HCl?
How does Aldoxorubicin HCl work?
What is Aldoxorubicin HCl used for?
Who makes Aldoxorubicin HCl?
What drug class is Aldoxorubicin HCl in?
What development phase is Aldoxorubicin HCl in?
What are the side effects of Aldoxorubicin HCl?
What does Aldoxorubicin HCl target?
Related
- Drug class: All antitumor antibiotic drugs
- Target: All drugs targeting DNA topoisomerase II
- Manufacturer: ImmunityBio, Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Solid tumors
- Compare: Aldoxorubicin HCl vs similar drugs
- Pricing: Aldoxorubicin HCl cost, discount & access